已收盤 09-20 16:00:00 美东时间
-0.410
-1.53%
Exelixis (NASDAQ:EXEL) underwent analysis by 5 analysts in the last quarter, re...
09-18 20:01
Exelixis (NASDAQ:EXEL) has been analyzed by 5 analysts in the last three months...
08-09 03:06
Exelixis, Inc. : H.c. Wainwright Raises Target Price to $29 From $28
08-08 18:12
Exelixis reports strong Q2 earnings with adjusted EPS of $0.84, surpassing estimates. The CONTACT-02 trial for mCRPC showed significant PFS benefit but OS did not achieve statistical significance. Exelixis plans to submit a supplemental FDA application in 2024.
08-08 02:15
RBC Capital analyst Gregory Renza reiterates Exelixis (NASDAQ:EXEL) with a Outperform and maintains $27 price target.
08-08 00:17
Analyst Silvan Tuerkcan from JMP Securities maintained a Buy rating on Exelixis...
08-07 12:45
Exelixis Inc : Leerink Partners Raises Target Price to $25 From $19
08-07 11:11
Exelixis Sees FY Total Revenues $1.975 Bln - $2.075 Bln
08-07 04:48
Exelixis Inc: Earned $150 Mln Cabozantinib Sales-Based Milestone From Ipsen
08-07 04:48
Exelixis Inc FY2024 Shr View $1.12, Rev View $1.88 Bln -- LSEG IBES Data
08-07 04:48